A medical device for left atrial appendage closure includes a support frame with a proximal collar and a distal collar, where the support frame is actuatable from a first constrained configuration to a second radially expanded configuration. A membrane is disposed on at least a portion of the support frame, and an engagement element is coupled to the distal end region of the support frame. The engagement element extends distally from the support frame and is configured to engage an inner surface of the left atrial appendage and prevent the support frame from sliding along the inner surface of the left atrial appendage during implantation.

The present disclosure relates generally to stents and methods for managing passage of material through a body lumen. In some embodiments, a medical stent may include a stent body defined by a hollow tubular elongate structure extending along a central axis, the stent body including a first portion and a second portion. The medical stent may further include a control region between the first and second portions, wherein in a first configuration the hollow tubular elongate structure of the control region is in a closed, twisted configuration, and wherein in a second configuration the hollow tubular elongate structure of the control region is in an open, expanded configuration.

Degree of occlusion is monitored for an occlusive device configured to occlude passage of fluid between two compartments in a lumenal space of a body of a patient. In some embodiments, changes in an electrical signal measured from the body of the patient are induced by perturbing the fluid; for example, by “tagging” a portion of fluid with a perturbation of temperature and/or composition. The degree of occlusion is estimated based on the measured changes. The electrical signal changes may be indicative of fluid movements redistributing the perturbed fluid among the two compartments; for example, by diffusion, mixing, and/or jetting of fluid.

Electrical field-guided positioning of a second device within a body cavity, using electrical field mapping information generated from electrical field measurements by electrodes of a first device. The first device, in some embodiments, is a catheter electrode probe, and the second device is an internally implantable and/or operated medical device. An exposed, electrically conductive portion of the second device is optionally configured to be used as an electrical field measuring electrode. A rule is applied to measurements made by this electrode to estimate its position within a body cavity. The rule is generated, in some embodiments, using measurements made by the first device. In some embodiments, electrical measurements are used to guide implantation verification. In some embodiments, electrical measurements are used to guide navigation at and through a septal wall between body cavities.

An implant (1) for the treatment of arteriovenous deformities, in particular aneurysms (2). In an expanded state the implant has a basic body (6) comprising of a proximal and a distal segment (7, 8), with the proximal and the distal segment (7, 8) being of dome-shaped configuration, with the convex side of the dome of the proximal segment (7) facing in the proximal direction and the convex side of the dome of the distal segment (8) facing in the distal direction, and wherein the proximal and the distal segment (7, 8) are connected to each other via a plurality of connecting struts (9). Alternatively, the implant (1) may have the shape of a closed tulip blossom. The inventive implant (1) is able to adapt well to the shape of the respective aneurysm (2).

Disclosed herein is an intrasacular aneurysm occlusion device with a linearly-aligned proximal-to-distal stack of embolic structures which is configured to be inserted into an aneurysm sac and then radially-expanded and longitudinally-contracted. The stack can be shaped like a 3D revolution of three single phases (or one and half full phases) of a sine wave around its central longitudinal axis. There can be openings in the stack which allow insertion of embolic material (e.g. coils, hydrogels, or congealing material) into the embolic structures.

What is disclosed are medical devices comprising a rounded, thin-walled, expandable metal structure (“ballstent”) and a flexible, elongated delivery device (“delivery catheter”) and systems and methods of use for treating saccular vascular aneurysms with the medical devices. Ballstents comprised of gold, platinum, or silver that can be compressed, positioned in the lumen of an aneurysm, and expanded to conform to the shape of the aneurysm are disclosed. The external surface of ballstents can be configured to promote local thrombosis and to promote the growth of tissue into and around the wall of the ballstent in order to seal the aneurysm and fix the ballstent in place in the aneurysm. The wall of the ballstent can also be configured to release drugs or pharmacologically active molecules, such as those that promote thrombosis, cell proliferation, extracellular matrix deposition, and tissue growth.

Methods for treatment of a cerebral aneurysm within a cerebral vasculature of a patient are described. A microcatheter and a device for treatment of the aneurysm are provided. The device is a self-expanding resilient permeable shell having a plurality of elongate resilient filaments with a woven structure. The plurality of filaments includes small and large filaments. The filaments are bundled and secured to each other at a proximal end. A ratio of the total cross-sectional area of small filaments to the total cross-sectional area of large filaments may be between 0.56 and 1.89. The distal end of the microcatheter is advanced to a region of interest within a cerebral artery. The device is advanced through the lumen and out of the distal end of the microcatheter such that the permeable shell deploys and expands within the cerebral aneurysm. The microcatheter is then withdrawn from the cerebral artery.

Devices and methods for occluding the left atrial appendage (LAA) to prevent blood from clotting within the LAA and subsequently embolizing, particularly in patients with atrial fibrillation. A foam implant encapsulated with a tough thromboresistent membrane is placed via transvascular means into the LAA and anchored with adhesives and/or mechanical anchors. Tissue over- and in-growth are optimized to anchor the implant in place and provide a permanent occlusion.

A method of reducing blood flow within an aneurysm includes: injecting a contrast agent into a blood vessel including an aneurysm; expanding a stent, from a delivery device, across the aneurysm; and confirming that a stagnated area forms in the aneurysm. The stagnated area can form a crescent shape, a mushroom shape, a hemispherical shape, and/or a flat side. Upon confirming that the stagnated area forms in the aneurysm, the delivery device can be withdrawn from the blood vessel. The stagnated area can include the contrast agent. If the stagnated area does not form in the aneurysm, a second occluding device may be deployed. After withdrawing the delivery device, substantially all of the aneurysm progressively thromboses.